Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
1 other identifier
interventional
60
1 country
1
Brief Summary
The purpose of this study is to investigate whether perioperative immunonutrition has additional effects on cell-mediated immunity in patients undergoing pancreaticoduodenectomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Jan 2013
Typical duration for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
October 5, 2013
CompletedFirst Posted
Study publicly available on registry
October 25, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2015
CompletedOctober 25, 2013
October 1, 2013
2.7 years
October 5, 2013
October 24, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
plasma resolvin E1, cell-mediated immunity
30 days
Secondary Outcomes (1)
infectious complication rate
30 days
Study Arms (2)
Perioperative
ACTIVE COMPARATOROral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
Preoperative
ACTIVE COMPARATOROral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
Interventions
Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
Eligibility Criteria
You may qualify if:
- patients undergoing pancreaticoduodenectomy
You may not qualify if:
- age younger than 18 years old
- ongoing infection
- gastrointestinal obstruction
- respiratory dysfunction
- cardiac dysfunction
- hepatic dysfunction
- renal failure
- history of recent immunosuppressive or immunological disease
- preoperative evidence of widespread metastatic disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chiba Universitylead
Study Sites (1)
Chiba University Hospital
Chiba, Chiba, 260-8670, Japan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Katsunori Furukawa, MD
Chiba University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
October 5, 2013
First Posted
October 25, 2013
Study Start
January 1, 2013
Primary Completion
September 1, 2015
Study Completion
September 1, 2015
Last Updated
October 25, 2013
Record last verified: 2013-10